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Objective: This study was to investigate the outcome of status epilepticus (SE)
associated with antiepileptic therapy during SE and in follow-up period, risk factors
including age, co-morbidities, pre-existing epilepsy, and etiology in the East-Hungarian
region.
Methods: A prospective cross-sectional database was compiled from outpatient files
between 2013 and 2017. Follow-up ended on 30.06.2018.
Results: One hundred and thirty five episodes (male: 68, 50.4%) were evaluated, mean
age and follow-up time being 64.1 ± 13.9 years and 39.9 ± 14.2 months, respectively.
Of the 89 patients with pre-existing epilepsy, 34 failed to visit the outpatient unit regularly.
Case fatality rate was 25.2% and 31 patients (30.7%) died after discharge due to
co-morbidities; their mean survival time was 10.44 ± 8 months. Focal, generalized and
combined type epilepsies were diagnosed in 67 patients (49.6%), 47 patients (34.8%),
and 21 patients (15.6%) of SE, respectively. Nine patients had non-convulsive SE (NCSE).
Mean seizure-free period was 6.8± 6.9 months. Patients taking carbamazepine (20.9%;
OR: 0.37, 95%CI: 0.16–0.82; p = 0.018), levetiracetam (27.5%; OR: 0.51, 95%CI:
0.27–0.97; p = 0.041), or valproate (11.1%; OR: 0.18, 95%CI: 0.05–0.61; p = 0.0043)
were expected to achieve seizure freedom after SE. The worst outcome was linked to
advanced age, etiology, new onset status epilepticus, NCSE, and focal status epilepsy.
Conclusion: This study highlights the importance of regular care and patient follow-up.
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INTRODUCTION
Status epilepticus (SE) is a condition and most extreme form of epilepsy (1), which leads to
abnormal and prolonged seizure (at least 5min). In case SE persists over 30min, it may have
severe long-term consequences (2). Referring to the new classification scheme of SE, there are two
operational dimensions of the definition: time point 1 (T1) is associated with abnormally prolonged
seizure, when therapy should be initiated, while time point 2 (T2) is related to the time of on-going
seizure activity involving a risk of long-term consequences (2).
SE is one of the most common neurological emergencies (1). It is a potentially life-threatening
situation which needs a prompt and particular treatment (3) in order to prevent cerebral damage
due to initial excitotoxicity (4). Treatment is urgent because GABA sensitivity decreases and the
sensitivity to excitotoxic neurotransmitters increases rapidly, leaving only a short time interval for
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effective treatment. SE may also have life-time consequences and,
especially in refractory SE, the probability of becoming epileptic
is higher (5).
Cases of reported refractory and super-refractory SE (SRSE)
are uncommon but very important clinical problems due to
treatment difficulties, consequences, and high case fatality (1, 2,
4). Nevertheless, they probably occur more often than thought,
especially if one thinks of non-convulsive SE. Five to ten percent
of refractory SE patients turn out to have super refractory SE (6).
The incidence of SE falls in the range of 10–41/100,000 (1).
Despite the newer generation of antiepileptic drugs (AEDs), the
management of epilepsy and SE has not been resolved yet (7).
In this study, the patients’ age and co-morbidities influenced
the outcome of SE (1). Common etiologies included non-
compliance, stroke, metabolic disorders, and alcohol withdrawal
among adult patients. Of the people with epilepsy, 15% had
SE during their lifetime; however, pre-existing epilepsy went
undiscovered in more than 50% of SE patients.
In the current study, we focused on the outcome (short
and long-term mortality and seizure freedom) of SE in view of
antiepileptic therapy during SE and in the follow-up period, risk
factors such as age, co-morbidity, pre-existing epilepsy, as well as
the underlying pathology, in the East-Hungarian region.
METHODS
Data were retrieved from the patients’ files, covering the period
between 01.01.2013 and 31.12.2017 in a retrospective view. The
subjects had been treated for SE at the neurointensive unit of
a tertiary teaching hospital and coded with status epilepticus
diagnoses in accordance with the International Classification of
Diseases by the World Health Organization (8). Each admission
of the same patient was considered as a single case. In this study,
the patients were followed-up until 30.06.2018. The department
provides care only for adult patients. The catchment area is
∼548,000 inhabitants.
In every case, data collection included issues as follows: age,
gender, cause, history of previous epilepsy, former intracranial
surgery, treatment with antiepileptic drugs before, during and
after SE, and other medicines regularly taken for CNS, MRI
scan, EEG, and comorbidities. The 21 EEG electrodes were
placed according to the International 10–20 system, and digital
recording was used. All EEGs were evaluated by a board-certified
clinical neurophysiologist. In the case of convulsive SE, EEG was
done to classify the type of the seizure (focal, or generalized).
According to the recommendations, and if it was clinically
reasonable (e.g., impairment of consciousness), a post-SE EEG
was done in order to exclude a transition to NCSE and tomonitor
the effectiveness of the therapy. NCSE was diagnosed according
to Beniczky et al. (9). Depending on the therapy and response
to it, EEG was repeated 24–48 h later. Unfortunately, continuous
EEG monitoring was not available at the time of the study.
The following age groups were considered for pooling: 18–39,
40–64, 65–80, and over 81-years-old.
Regarding the status epilepticus, the following data were
collected: type of seizure (focal, secondary generalized,
generalized, non-convulsive, and unknown seizures according to
the ILAE definition (10, 11), antiepileptic treatment, besides the
benzodiazepine used primary and in case of survival, used for
maintenance therapy.
Notable co-morbidities were as follows: diabetes mellitus,
hypertension, hypercholesterolemia, renal failure, liver failure,
heart failure, cancer, Parkinson’s disease, stroke etc.
New onset status epilepticus (NOSE) was considered if the
patient did not have known seizures previously.
Refractory SE (RSE) was diagnosed if the patients did not
respond to standard SE treatment, i.e., receiving adequate doses
of initial benzodiazepine followed by a second AED (12). In case
of SRSE, the definition of Shorvon et Ferlisi was used, i.e. SE
could not be terminated or it recurred within 24 h; also, when
propofol or midazolam were necessary, including cases in which
SE recurred on the reduction or withdrawal of these drugs (4).
Statistical Analysis
Statistical analysis was carried out using the SPSS for Windows
19.0 (SPSS Inc. Chicago, USA) and Microsoft Office Excel 2007.
Beside the basic statistics, two-sample T-test, and Fisher’s exact
test were used to analyse our patients’ data. Categorical variables
were assessed using Pearson χ2 test. Odds ratios were calculated.
Significant differences were considered if p< 0.05.
Ethical approval was obtained from the Regional and
Institutional Ethics Committee (DE KK RKEB/IKEB:
5037-2018).
RESULTS
Basic Characteristics
The diagnosis of SE was established in 121 patients (male: 61;
50.4%). As eight patients (6.6%; male 3, female: 5) had had two
or more admissions due to SE, a total of 135 episodes (male:
68, 50.4%) were evaluated. The patients’ mean age was 64.1 ±
13.9 years.
Based on the distribution by age, 87 (71.9%) of the
patients were between 40 and 80 years old. Among them, the
working/active age group included 50 (41.3%) patients.
Themean follow-up time was 39.9± 14.2months. The longest
follow-up was 66 months and the shortest was 7.5 months.
The prevalence of SE was in the range of
9.4–14.7/100,000 inhabitants/year.
The seasonality of prevalence showed the highest occurrence
in December and January followed by August.
According to the classification of Trinka et al. (2), previous
epilepsy was known in 89 patients (73.6%), the mean age being
62.2 ± 14.4 years. Of the 32 patients with unknown previous
epilepsy (26.4%; mean age: 70.1 ± 12.35 years), 22 died during
hospitalization, all could be classified as symptomatic SE. Among
the survivors (10 patients), there was only one patient who
had no symptomatic abnormality in the background. So only
this one could fit the definition of the ILAE epilepsy diagnosis.
One third of the patients did not visit epilepsy outpatient units
regularly. Of the 89 patients with known epilepsy, 37.1% had
focal seizures without secondary generalization and 23.6% had
focal seizures with secondary generalization. Among the patients
with generalized epilepsy (39.3%) seizure types were as follows:
generalized tonic-clonic, myoclonic and absence, i.e., 33, 1 and
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TABLE 1 | Distribution of causes in different age groups.
Etiology 18–39 years-old
N = 15
(A/B)
40–64 years-old
N = 44
(A/B)
65–80 years-old
N = 51
(A/B)
≥81 years-old
N = 25
(A/B)
Tumor; primary CNS tumor 0 8;5
(5/3)
9;5
(6/3)
1;1
(1/0)
Systemic infection 4
(4/0)
9
(7/2)
13
(9/4)
13
(6/7)
Meningitis, encephalitis 2
(2/0)
1
(0/1)
1
(1/0)
0
Alcohol 2
(2/0)
17
(12/5)
5
(4/1)
2
(2/0)
Congenital abnormality 7
(6/1)
2
(2/0)
0 0
Metabolic disorder 0 2
(2/0)
4
(4/0)
3
(3/0)
Non-compliance 0 11
(11/0)
5
(5/0)
2
(2/0)
Stroke; ischemic 0 10;8
(6/1)
14;5
(12/2)
8;8
(8/0)
Intracranial traumatic bleeding 0 2
(2/0)
1
(0/1)
0
Sleep deprivation 2
(2/0)
0 0 0
Unknown 1
(1/0)
1
(0/1)
5
(5/0)
2
(0/2)
(A patient may have multiple etiologies; the data are discussed from the point of view of SE).
N: number of patients.
(A/B): number of patients with pre-existing epilepsy/ number of new onset epilepsy cases.
FIGURE 1 | Most common causes of status epilepticus among people with a history of epilepsy and NOSE patients (*A patient may have multiple etiologies; the data
are discussed from the point of view of SE).
1 cases, respectively. Only one patient had a history of Lennox-
Gastaut syndrome. Altogether, 91% had symptomatic epilepsy
among patients with a history of this disease.
Among all the patients with SE, 78 and 23 patients had RSE
and SRSE, respectively. New onset refractory status epilepticus
(NORSE) was observed in 18 patients among those having
refractory SE. The number of NOSE and NORSE cases with
undetermined causes were so few (3 and 2 patients, respectively)
that far-reaching conclusion cannot be drawn.
All of the SE patients had hypertension.
Etiology
Unknown etiology of SE was revealed in nine cases but in
the majority of the patients, several causes were identified. In
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TABLE 2 | Number of prescribed AEDs on discharge and the outcome as of 30 June 2018.
AED Number of
prescriptions
Number of seizure
free patients
Odds ratio
(95% CI; p-value)
Number of deaths Odds ratio
(95% CI; p-value)
Levetiracetam 69 19 0.51 (0.27–0.97; 0.041)* 25 0.95 (0.51–1.76; 0.88)
Carbamazepine 43 9 0.37 (0.16–0.82; 0.018)* 18 1.31 (0.65–2.63; 0.47)
Valproate 27 3 0.18 (0.05–0.61; 0.0043)* 8 0.68 (0.28–1.65; 0.52)
Oxcarbazepine 13 1 0.13 (0.02–1.01; 0.033) 4 0.74 (0.22–2.5; 0.77)
Lamotrigine 14 5 0.94 (0.3–2.93; 1) 3 0.44 (0.12–1.63; 0.26)
Lacosamide 16 3 1.1 (0.25–4.83; 1) 8 1.73 (0.62–4.82) 0.42
Clonazepam 6 2 0.85 (0.15–4.75; 1) 3 1.73 (0.34–8.85; 0.67)
Clobazam 4 0 N/C 1 0.56 (0.06–5.5; 1)
Phenytoin 2 0 N/C 2 N/C
Rufinamide 2 0 N/C 0 N/C
Primidone 1 0 N/C 1 N/C
Topiramate 1 1 N/C 1 N/C
Zonisamide 1 1 N/C 1 N/C
, Older type AEDs. N/C not computable. “*” represent statistically significant values.
the different age groups, the particular causes showed varying
pictures in terms of etiology (Table 1).
Among patients with previously known epileptic seizures,
the most common causes of status epilepticus were infections,
stroke, alcoholism and non-compliance (Figure 1) while
among patients with NOSE, infections, alcoholism, stroke
and tumor were at the top of the list (Figure 1). Only two-
thirds of the people with epilepsy were regularly supervised
by an epileptologist prior to SE; these patients all had
refractory epilepsy.
Just under 50% of cases were focal, and focal epilepsy with
secondary generalization (41 patients; 30.4%; 26 patients; 19.3%
respectively); generalized epilepsy was diagnosed in 34.8% (47)
of patients and combined-type epilepsies amounted to 15.6%
(21 patients) of status epilepticus. Nine patients were diagnosed
with non-convulsive status epilepticus (NCSE). Of them, three
patients had generalized seizure and four patients focal epilepsy
with secondary generalization prior to NCSE.
Antiepileptic Drug Treatment
All known people with epilepsy took one, two, and three
or more types of AEDs, 34 (52.3%), 21 (32.3%), 12 (18.5%),
respectively. Interestingly, if we compare the pattern of AED
use among SE patients with a history of epilepsy with the data
of people with epilepsy in our outpatient care unit (published
earlier) (13), the differences are significant (p = 0.0014) (34
[52.3%] vs. 894 [69.7%]; 21 [32.3%] vs. 286 [22.3%]; 12 [18.5%]
vs. 102 [8%]).
In order to control seizures, one, two, and three or more
AEDs were used in 15 patients (11.1%); 41 patients (30.4%);
and 79 patients (58.5%); respectively, subsequent to the first
line benzodiazepine (diazepam or clonazepam) during SE. No
significant difference was found between the number of AEDs
taken before SE and the AEDs administered during SE.
General anesthesia was necessary in 23 (17%) patients.
Midazolam, ketamine and propofol were administered in 16
TABLE 3 | Death and survival of patients with status epilepticus.
Death ratio Survival
All During
hospitalization
After
discharge
Number of patients 65 34 31 70
Mean age ± SD
(year)
72.7 ± 9.9 75.4 ± 9.3
(ref.)
68.7 ± 10.7* 55.8 ± 14.6*
Male 29 17 12 39
Female 36 17 19 31
Mortality (%) 48.1 25.2 23 N/A
N/A not applicable.
*p ≤ 0.05.
(11.9%), 4 (3%), and 9 (6.7%) cases, respectively. Seven of the
patients had generalized type of epilepsy, eleven patients had
focal epilepsy with or without secondary generalization (7, 4
respectively), four patients suffered from a combined type and
one patient had NCSE.
Certain older generation AEDs such as valproate, clonazepam,
phenytoine, and carbamazepine (supp.) as well as newer type
ones including levetiracetam, and lacosamid were used in the
treatment of SE. Even if a nasogastric tube had to be inserted
treatment with AEDs such as oxcarbazepine and lamotrigine
were continued.
Among the patients who survived SE (101 patients), 85.1%
(86 individuals) took one or two AEDs (49 and 37 patients,
respectively) at discharge to maintain seizure freedom. Only
15 patients were discharged with three or more AEDs to
take. The number of AEDs per patient was 1.7 ± 0.7. The
number of AEDs is significantly (<0.0001) higher if the results
of patients surviving SE and our previous findings (1.4 ±
0.56) of people with epilepsy at the outpatient department are
compared (14).
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The prescriptions of newer type AEDs were significantly
higher at discharge than at admission (p < 0.005), but
the number of older type AEDs showed a variety as well
(Table 2). Among our patients, the ones taking carbamazepine,
levetiracetam and/or valproate had the highest probability to
achieve seizure freedom. The choice of AED on discharge had
no significant effect on mortality (Table 2).The need for general
anesthesia was independent of the add-on administration of
levetiracetam and/or lacosamide in SRSE.
Outcome
The discharged patients’ mean survival time was 10.44 ± 8
months. Seventy patients have survived SE (mean age: 55.8 ±
14.6 years) and 25 of them achieved seizure freedom. The mean
seizure free period was 6.8± 6.9 months (the shortest seizure free
time was 1 day and the longest one was 5 years).
Sixty-five patients (53.7%) died during the period investigated,
primarily due to co-morbidities especially common in the
advanced age group. Case fatality rate was 25.2% (Table 3) among
all examined SE patients 22 of which suffered from NOSE. The
death rate among NOSE patients was significantly higher than
the mortality among previously people with epilepsy (p= 0.009).
Young patients had a much better chance to survive (Table 3).
There was no difference betweenmale and female mortality rates.
If the time course of death was examined, in-hospital case fatality
was the highest and a second peak was detected at 6 months.
Mortality increased by age (p < 0.0001). Apparently, younger
patients died after discharge.
Among patients with pre-existing epilepsy, the highest
mortality was observed in case the duration of epilepsy was < 1
month (Figure 2).
The leading causes of SE among deceased patients were stroke
(42.86%), tumor (33.33%) and infection (23.81%). Mortality
within a co-morbidity group was due to tumor (28%), stroke
(25.71%), and infection (20.83%). The probability of death
increased significantly (p = 0.0021) with the number of co-
morbidities (Table 4). All patients who had had cancer died.
Most of the deceased patients had focal epilepsy with or
without secondary generalization (61.5%), 21.5% of patients had
generalized seizure (Table 5). NCSE was observed in 12.3% of
the SE patients. By the types of SE, NCSE showed the highest
mortality, followed by focal epilepsy (59.7%) and generalized
epilepsy (31.1%).
The number of AEDs given to cease seizures were inconsistent
with mortality.
Using older and/or newer type of AEDs (administered as
second or third line drugs) did not influence the odds of death
during the status epilepticus.
The AEDs used during SE did not influence mortality
significantly. General anesthesia did not influence survival and
seizure freedom significantly.
Co-administered other drugs belonging to the ATCN05 group
(47 patients) before SE did not influence the seizure freedom after
SE, but the mortality among patients taking at least one drug was
favorable (OR: 0.41 95%CI: 0.1969–0.8571; p = 0.02). They took
chlordiazepoxide, alprazolam, antidepressants, etc.
DISCUSSION
Basic Characteristics
SE, also known as status epilepticus, is an important and life-
threatening form of epilepsy. This study is the first in our region
to summarize SE cases and evaluate the treatment and outcome.
Just as in other SE studies, the gender ratio was nearly equal
(15) and more than half of the patients were elderly. Our research
is of special importance since almost half of the patients were still
active, i.e., they belonged to the working-age population. Among
middle-aged patients, the most common etiologies included
alcohol consumption, non-compliance and stroke. Meanwhile,
infection and stroke most often affected elderly patients. The
FIGURE 2 | Duration of pre-existing epilepsy and status epilepticus mortality. Only one in nine NCSE patients survived (p = 0.014).
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TABLE 4 | Outcome by etiology.
Etiology Dead Alive Odds ratio 95% Confidence Interval p-value
Lower limit Upper limit
Tumor (CNS) 17*(6) 1 (1) 25.78 3.34 198.88 <0.0001
Systemic infection 23 16 2.02 0.98 4.19 0.067
Alcohol 9 17 0.59 0.25 1.41 0.29
Meningitis, encephalitis 1 3 0.39 0.04 3.83 0.63
Congenital abnormality 1 8 0.15 0.018 1.2 0.08
Metabolic disorder 5 4 1.37 0.35 5.3 0.74
Non-compliance 5 13 0.42 0.14 1.24 0.14
Stroke (ischaemic) 13 (1) 19 (13) 0.78 0.36 1.7 0.56
Intracranial traumatic bleeding 1 2 0.59 0.053 6.66 1
Unknown 2 7 0.32 0.07 1.6 0.18
(A patient may have multiple etiologies; the data are discussed from the point of view of SE).
*p ≤ 0.05.
TABLE 5 | Mortality by seizure type.
Seizure type Dead Alive Odds ratio (95% CI;
p-value)
Generalized 15 31* 0.38 (0.18–0.8; 0.0075)*
Focal 39* 27 2.39 (1.2–4.77; 0.01)*
Focal without sec. gen. 25* 15 2.29 (1.07–4.89; 0.024)*
Focal with secondary
generalization
14 12 1.33 (0.56–3.13; 0.33)
bCombined 10 11 0.98 (0.38–2.48; 1)
NCSE at onset 1 1 1.08 (0.07–17.6; 1)
All patients with NCSEa 8* 1 9.86 (1.18–79.4; 0.014)*
*p ≤ 0.05.
a This group contained all patients who had not only NCSE.
b Combined: during treatment several types of seizure originating from different foci.
onset of stroke was typical at an older age but in our cohort—
similarly to alcoholism—the incidence of stroke was high in
younger patients.
No strict seasonality was observed but data aggregation by
month showed peaks in January and December during the
winter, and in August during the summer. There was no close
relation between SE and holidays either. Although this is an
interesting finding, we could not find unequivocal clarification
for it. However, it must be noted, that stable and unstable
atmospheric pressure and temperature go from one extreme to
the other in Hungary in the aforementioned months. Motta
et al. (16) also reported increased seizure frequency in unstable
weather conditions.
A quarter of the patients had NOSE. They were older than
those with previously diagnosed epilepsy, moreover, they usually
suffered from severe co-morbidities. Their history of epilepsy
started with SE and mortality among them was higher. Despite
the adequate therapy of SE, their prognosis was poor. Based
on our results, previous epilepsy was 74.4%, quite similar to
those of a Norwegian study (73%) (15), but lower (43%) than
in a large prospective cohort study (17). It should be noted
that the latter publication only examined refractory or super
refractory SE cases. On the basis of our findings, one third
of the patients diagnosed with epilepsy did not visit their
epileptologist on a regular basis. This is regarded to be as an
example of non-compliance/adherence behavior because, in this
country, yearly follow-up by an epileptologist is necessary to
subsidize AED prescriptions. So, we think that this type of
non-adherence may contribute to the evaluation of SE. This
emphasizes the importance of care in preventing SE. Regular
care is of similar importance as, for example, preventing SUDEP
(sudden unexpected death in epilepsy) (18).
Etiology
Infection was the leading cause of SE in our cohort. Among
the patients with pre-existing epilepsy, non-compliance,
alcoholism and stroke followed infections by frequency,
while alcoholism, stroke and tumor were the most common
etiologies among NOSE patients. In a Norwegian SE cohort,
cerebrovascular diseases, intracranial tumors, low AED levels,
and neurodegenerative disorders (15) were listed as the most
common cause for SE.
Alcohol- and stroke-related cases of SE were less common in
our study than in an article by Leppik (19). He found stroke to
have caused 52.3% of the cases of SE among the elderly adults and
17.7% in middle-aged adults, while, in our study, the figures were
16.3 and 7.4%, respectively. It is worth mentioning that stroke
was remarkable in younger age groups and among the 65–80
year-old patients. As far as stroke patients are regarded, ischaemic
stroke occurred more frequently in all age groups, except for
the patients aged between 65 and 80 years; the latter group was
more often hit by haemorrhagic stroke. The high occurrence
of haemorrhagic stroke in SE is interesting, because ischaemic
stroke ismore frequent in the elderly. All SE patients had a history
of hypertension, which is one of the most important risk factors
of stroke.
In a recently published study, Ulvin et al. found the level of
generalized convulsive SE at 67% in the non-refractory SE group,
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and at 47% in refractory SE (15). In contrast with Ulvin et al. in
our study, the focal form of SE was most common, just as in the
publications by Sutter et al. (20) and Novy et al. (21). Possible
contradictions among these findings may be due to disparities
in etiology.
Treatment
The number of AEDs prior to status epilepticus did
not influence the number of AEDs used to control SE.
Compared to other SE studies, fewer patients needed general
anesthesia (17 vs. 41% by Ulvin; and 9.8% by Delaj). The
choice of the AED did not influence the need for general
anesthesia. Some medications (e.g., benzodiazepines)
used in SE may have severe adverse drug reactions
like respiratory depression, so for NCSE patients (e.g.,
stroke) a good alternative therapy might be newer type of
AED (22).
Most of the patients needed only one or two AEDs at
discharge, and newer types of AEDs were in favor: we assumed
that the role of drug interactions among multimorbid patients
was an important argument.
Seizure freedom was significantly longer among patients
taking levetiracetam, carbamazepine, and valproate.
Outcome
In accordance with the literature, mortality from SEwas high (19)
and age dependent.
In-hospital mortality was 25%, in SE studies showing high
variability in different studies (9–37%) (17, 20, 21, 23). However,
the mortality in pre-existing epilepsy was less than in NOSE in
our study. According to our findings, NOSE could be considered
as a high risk factor for mortality (Figure 2) emphasizing the
importance of NOSE.
Etiology also had a considerable impact on the outcome
beyond SE. All patients who had cancer died.
In focal SE mortality was significantly higher than in the
generalized type. Focal neurological lesions such as stroke and
tumors caused mostly focal epileptic seizures, which may explain
the outcome (Table 5).
The number and type of older and newer AEDs did
not influence the outcome of SE. In terms of seizure
remission, there were no significant differences between
new and old type AEDs; important was to terminate
SE (24). In his publication, Schmidt came to a similar
conclusion concerning refractory epilepsy: newer types
of AEDs were not more efficient than the old ones (22).
SE might also be regarded as an extreme refractory type
of convulsion.
Only one out of nine patients survived NCSE. All of these
patients had severe co-morbidities and were of advanced age.
In general, the low occurrence of NCSE might be due to being
underdiagnosed in non-neurological wards, where the patients
were treated for their primary diseases on one hand, on the
other hand in lack of long-term EEG on the intensive care
unit and Stroke Unit ward less patients are discovered with
NCSE. Implementing long-term EEG on these wards in case of
predictors (large infarct size, large atherothrombotic etiology,
high NIHSS score on admission) would help the diagnosis of
NCSE and lead to early treatment and better outcome (25).
We are aware that our study has several limitations.
First of all, the current study is an observational study and
not a randomized, controlled trial. Therefore, selection bias
might have affected the results. Secondly, treatment options
and definitions have changed during the investigated period.
Unfortunately, because the several aetiological and triggering
effects only low case numbers would have been achieved with
subgroup analysis. Nevertheless, this study has invaluable assets
including prospective data collection and detailed information
on all subjects. Further strength of our study may be the
real-life data sets leading to the better understanding of
real-life clinical settings and the outcome of routine status
epilepticus treatment.
In summary, several conditions complicate the picture
in everyday practice so real-life data are essential in
order to understand real patients in the ward. No strict
seasonality of SE cases was observed. The worst outcome of
SE was linked to advanced age, etiology, new onset status
epilepticus (NOSE), NCSE and focal status epilepsy. The
choice of the AED did not influence the need for general
anesthesia. The administration of newer type AEDs in
the SE treatment may have an impact on the prescription
pattern after discharge, however older type AEDs are a
reasonable choice to achieve seizure freedom after SE. Seizure
freedom was significantly higher among patients taking
levetiracetam, carbamazepine and valproate. This study
highlights the importance of regular care and follow-up
of patients.
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